Heart Disease Trial, Recruiting NCT06208007 Sponsor: University Medical Center Goettingen Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06208007
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 60 years
  • People who have high blood pressure (either a top number of 140 or more, a bottom number of 90 or more, or who take 2 or more blood pressure medications)
  • People who have Type 1 or Type 2 diabetes
  • People who have a heart rhythm condition called atrial fibrillation
  • People who have chronic kidney disease (based on specific kidney function or protein levels in the urine — confirm with trial site)
  • People with a body mass index (BMI) of 30 or higher
  • People who experience shortness of breath or limitations with moderate physical activity or less (known as NYHA Class II or above — confirm with trial site)
  • People with a specific heart measurement result above a certain threshold, detected during a heart ultrasound (E/e' greater than 8 — confirm with trial site)

Who may not be able to join:

  • People whose heart's pumping function is below 50% (based on a heart ultrasound measurement)
  • People with significant heart valve problems rated at Grade III or higher
  • People who have previously had a heart valve repaired or replaced through surgery or a procedure
  • People who have abnormal movement in sections of the heart wall (detected on a heart scan)
  • People whose breathlessness is known to be caused by a lung or breathing condition
  • People who are in atrial flutter or atrial fibrillation at the time of their examination
  • People who have certain specific heart muscle conditions, including hypertrophic, restrictive, arrhythmogenic, or dilated cardiomyopathy, or conditions such as cardiac amyloidosis, sarcoidosis, or toxic cardiomyopathy
  • People who have previously had a heart transplant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Medical Center Goettingen
Registry
ClinicalTrials.gov
Start date
23 February 2024
Est. completion
1 January 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Change in HFA-PEFF-Score; Development of HFpEF; Composite endpoint cardiovascular events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov